Serelaxin-FDA staff review recommends against Novartis heart failure drug 2014
(0)
No of Views (
3480)
Serelaxin-FDA staff review recommends against Novartis heart failure drug 2014 A drug to treat acute heart failure made by Novartis AG should not be approved because there is insufficient evidence to show it improves symptoms, according to an initial review by the U.S. Food and Drug Administration. The review, posted on the FDA’s website on Tuesday, comes two days ahead of a meeting of outside advisors who will make their own recommendation on whether the drug should be approved. The FDA is not ...
Read More